大环状钆对比剂钆布醇极高累积剂量后未增强MR成像中齿状核信号增强的观察性研究
回顾性纳入17例接受10-44次大环状钆对比剂钆布醇(0.1 mmol/kg)的高级别胶质瘤患者,在未增强T1加权MR图像上评估齿状核信号增强。平均给药22.2±10.6次、历经706天±454天,齿状核归一化信号强度平均变化为0.03±0.05(P=.016),与给药次数呈线性相关(r=0.69,P=.002);2例接受37次和44次给药的患者可见肉眼可辨的信号增强。
要点
- 多次大环状钆对比剂给药后,齿状核T1加权信号呈剂量依赖性轻度升高。
- 齿状核归一化信号强度平均变化0.03±0.05,与给药次数线性相关(r=0.69)。
- 仅接受37次和44次给药的两例患者出现肉眼可辨的齿状核信号增强。
核心结论
- 多次注射大环状钆对比剂后,齿状核出现幅度小但统计学显著的剂量依赖性T1加权信号增强;在对比度优化图像上,接受37次和44次标准剂量大环状钆对比剂的两例患者可见肉眼可辨的齿状核增强。
研究设计与样本
- 回顾性观察性研究,经地区伦理委员会批准,纳入17例接受10-44次大环状钆对比剂钆布醇(0.1 mmol/kg体重)给药的高级别胶质瘤患者。
关键影像表现/征象
- 在优化窗宽窗位下,2例分别接受37次和44次大环状钆对比剂注射的患者可见肉眼可辨的齿状核信号增强。
- 齿状核信号强度以脑桥信号强度归一化后,基线至末次检查的归一化信号强度变化均值大于零(0.03±0.05,P=.016)。
诊断标准与关键数值
- 齿状核归一化信号强度(nSIDN)定义为齿状核信号强度除以脑桥信号强度。
- 大环状钆对比剂给药次数与基线至末次检查的nSIDN变化呈线性相关(r=0.69,P=.002),与所有基线后检查nSIDN平均变化亦呈线性相关(r=0.77,P<.001)。
- 平均大环状钆对比剂给药次数为22.2±10.6次,给药历经706天±454天。
临床应用与阅片要点
- 对多次接受大环状钆对比剂的患者,可在未增强T1加权图像上采用优化窗宽窗位观察齿状核信号变化。
- 齿状核信号强度测量时以脑桥信号强度归一化,并记录大环状钆对比剂累积给药次数。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To test for measurable visual enhancement of the dentate nucleus (DN) on unenhanced T1-weighted magnetic resonance (MR) images in a cohort of patients with a primary brain tumor who had not received linear gadolinium-based contrast agents (GBCAs) but had received many injections of macrocyclic GBCAs. Materials and Methods Seventeen patients with high-grade gliomas who had received 10-44 administrations of the macrocyclic GBCA gadobutrol (0.1 mmol/kg of body weight) were retrospectively included in this regional ethics committee-approved study. Two neuroradiologists inspected T1-weighted MR images with optimized window settings to visualize small differences in contrast at the baseline and at the last examination for the presence of visual DN signal enhancement. Signal intensity (SI) in the DN was normalized to the SI of the pons, and a one-sample t test was used to test for differences between baseline normalized SI (nSI) in the DN (nSIDN) and the average change in nSIDN of all postbaseline MR imaging sessions (ΔnSIDNavg) or the change in nSIDN from baseline to the last MR imaging session (ΔnSIDN). Linear and quadratic correlation analyses were used to examine the association between the number of macrocyclic GBCA administrations and ΔnSIDN or ΔnSIDNavg. Results The mean ± standard deviation number of macrocyclic GBCA administrations was 22.2 ± 10.6 administered throughout 706 days ± 454. Visually appreciable signal enhancement was observed in two patients who had received 37 and 44 macrocyclic GBCA injections. Mean ΔnSIDN was greater than zero (0.03 ± 0.05; P = .016), and there was a significant linear association between the number of macrocyclic GBCA injections and ΔnSIDN (r = 0.69, P = .002) and ΔnSIDNavg (r = 0.77, P < .001). Conclusion A small but statistically significant dose-dependent T1-weighted signal enhancement was observed in the DN after multiple macrocyclic GBCA injections. Visually appreciable enhancement in the DN was observed on contrast-optimized images in two patients who had received 37 and 44 standard doses of macrocyclic GBCAs. © RSNA, 2017 Online supplemental material is available for this article.
引用
- Bjørnerud A, Vatnehol SAS, Larsson C, et al. Signal Enhancement of the Dentate Nucleus at Unenhanced MR Imaging after Very High Cumulative Doses of the Macrocyclic Gadolinium-based Contrast Agent Gadobutrol: An Observational Study. Radiology. 2017. PMID: 28885891. doi:10.1148/radiol.2017170391
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。